Story
Sandvik Shares Tumble as Q2 Order Intake Misses Forecasts

Summary
Shares in Swedish engineering group Sandvik fell sharply after its second-quarter order intake failed to meet analyst expectations, raising concerns about future demand despite record revenue and profit.
Shares of Sandvik (STO:SAND) plunged more than 7% on Friday after the Swedish engineering group reported second-quarter order intake that fell short of analyst consensus, overshadowing an otherwise strong report with record revenue and profit.
Orders Miss Overshadows Profit Beat
Investors focused on the company's order intake, a key forward-looking indicator for industrial firms, which came in below expectations. The miss sparked concerns about the near-term demand trajectory for Sandvik's products and services.
Key figures from the Q2 2026 report include:
- Order Intake: SEK 37.80 billion, missing the consensus estimate of approximately SEK 39.24 billion.
- Revenue: SEK 36.75 billion, beating analyst expectations.
- Adjusted EBITA: SEK 8.31 billion, which also topped market forecasts.
AdDespite the beats on revenue and profitability, the market prioritized the weaker-than-expected orders as a signal of potential future softness.
Market Reaction and Context
The negative reaction was amplified by a broader risk-off sentiment in global markets. Stockholm’s OMXS30 index was trading lower, as were major U.S. benchmarks, providing no support for the stock-specific news.
Analyst sentiment was already mixed heading into the earnings release. According to Investing.com, at least one major Nordic bank held a sell recommendation on the stock, citing concerns that recent profitability gains driven by tungsten prices are temporary and likely to normalize from 2027 onwards. The combination of the forward-looking order miss and a weak market backdrop fueled the significant sell-off.
Read next
More on Stocks
Polymarket Sues NY Attorney General in Escalating Dispute Over Prediction Market Regulation
Prediction market platform Polymarket has filed a lawsuit against New York Attorney General Letitia James, seeking to block state regulation just hours after her office sued the company for allegedly promoting illegal gambling.

ADARx Pharmaceuticals Prices IPO at $17 Per Share, Raising $446.3 Million
Biotechnology firm ADARx Pharmaceuticals has priced its initial public offering of 26.25 million shares at $17.00 each, aiming to raise approximately $446.3 million. The IPO is accompanied by a concurrent private placement with pharmaceutical giant AbbVie.

OpenAI to Preview Cybersecurity-Focused GPT-6 Model, Fortune Reports
The AI research firm is expected to unveil GPT-6 Cyber within days at its developer event, according to a report, highlighting the growing focus on AI for combating security threats.

Tesla to Formally Launch Semi Truck Production at Nevada Factory Event
Tesla is officially rolling out its long-awaited Semi electric truck at an inauguration event for its Nevada factory, marking a key milestone years after the vehicle's initial unveiling.